A naukri.com initiative
Bioengineer
1d
72
Image Credit: Bioengineer
Research Finds Genetic Mutation in Certain Ashkenazi Jewish Men Associated with Elevated Prostate Cancer Risk
- Researchers have identified a genetic mutation, F722fs in MMS22L, associated with increased prostate cancer risk in Ashkenazi Jewish men.
- Frameshift mutations like F722fs alter genetic code, affecting protein synthesis and contributing to oncogenesis.
- MMS22L is crucial for DNA repair, and the F722fs mutation impairs this function, increasing prostate cancer vulnerability.
- Study analyzed gene variants in Ashkenazi Jewish men, with MMS22L showing strong association with prostate cancer risk.
- The F722fs mutation in MMS22L is linked to nearly five times higher risk of prostate cancer in this population.
- Mutation carriers may also exhibit aggressive tumor phenotypes, affecting disease aggressiveness and treatment decisions.
- MMS22L's role in response to PARP inhibitors suggests potential for personalized treatment strategies for mutation carriers.
- Research indicates the mutation's impact on DNA repair and tumor behavior, emphasizing the need for further studies and personalized screening.
- Study underscores the importance of genetic insights and population-specific data in precision oncology, particularly in unique populations like Ashkenazi Jews.
- Team's collaborative efforts have shed light on genetic factors impacting cancer genomics and patient care, with potential implications for genetic screening and therapies.
Read Full Article
4 Likes
For uninterrupted reading, download the app